Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab in advanced neuroendocrine neoplasms
NCT03095274Phase 2Completed
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Apr 2017
- Primary completion
- Nov 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in Neuroendocrine Neoplasm (NEN), Neuroendocrine neoplasm (NEN), sponsored by Spanish Group of Neuroendocrine Tumors. Started Apr 2017; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
Neuroendocrine Neoplasm (NEN)Neuroendocrine neoplasm (NEN)
Beyond the preview
Go deeper on NCT03095274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03095274.